NYSE American
-
SunLink Health Systems Receives NYSE American Notice of Delisting Concern
SunLink Health Systems received a deficiency letter from NYSE American for failing to hold its annual stockholder meeting. While its stock will continue trading, it will be flagged with a “.BC” indicator. This issue is unlikely to affect SunLink’s proposed merger with Regional Health Properties, scheduled for a shareholder vote soon. SunLink must hold its annual meeting by June 30, 2026, to regain full compliance if the merger is terminated.
-
Dr. Ashley’s Limited and Impact BioMedical Inc. to Merge Strategically
On June 23, 2025, Dr Ashleys Limited and Impact BioMedical Inc. announced a merger deal. Dr. Ashleys will acquire Impact BioMedical through a reverse merger, creating a new entity listed on the NYSE American. This strategic alliance merges Impact BioMedical’s innovative patents with Dr Ashleys’ resources and global reach, aiming to expedite the development of impactful therapies and expand global market access for biomedical advancements.
